African Vaccine Manufacturing Initiative

Advancing Vaccine Development and Manufacturing in Africa

Session 4
Knowledge Cafe

Freetown, Sierra Leone

24 – 25 September 2018

OBJECTIVE

Inputs on
Advancing Vaccine Development & Manufacture in Africa

The development of a strategy with national, regional, and continental partners perspectives in the context of strengthening national health security.

- **Importance of vaccine development and manufacturing capacity in Africa.**

- **AVMI Value Proposition**

- **Identifying, securing and working with Champions**

- **Developing the concept of a Ministerial Conference on Vaccine Development and Manufacture in Africa**

PROCESS

Participants will be grouped into 4.

- The task of each group is to **discuss and provide inputs on** the topic assigned to each table

- **A table host (facilitator)*** will facilitate the discussion, document contributions of the groups, brief the new groups on the work done by the previous group

- **A table documenter (note taker)*** will take the notes on the proceedings of the discussion, assist the table host in briefing incoming team and in reporting back to the plenary

- The **rest of the members will move from one table to the next** and **add value to the work** already done.

- The **facilitators or note takers** will report to the plenary

* The facilitator and note taker will stay on the assigned table.

PROCESS

Timing

- **Groups will switch tables periodically** – each group will address each of the table topics

- For the first round of discussions: 25 min

- Rounds 2 and 3: 20 min each

- Final round: 15 min   (adding to the already generated input should be easier and will take less time).

PROCESS

Importance of Vaccine Development & Manufacture

Round 1: 25 min
Round 2: 20 min
Round 3: 20 min
Round 4: 15 min

MCVDMA

Advocacy Champions

Table 1

Goal: **Identify the importance of vaccine development and manufacture in Africa**

1. Why is vaccine development and manufacture in Africa important?

2. Who are the key stakeholders who need to understand and support the above message?

3. What are the challenges to delivering above message to key stakeholders and how do we deliver the above message?

(Table hosts to capture any other off topic ideas)

Table 2

Goal: Refine and Sharpen AVMI's Value Proposition

AVMI needs to develop further as an organization by means of expansion and differentiation of activities. For this process AVMI seeks support from funders and stakeholders that work on vaccine manufacturing and vaccination in general in Africa. In order for AVMI to engage possible funders and partners, a document needs to be developed encompassing all relevant aspects of the value AVMI will deliver.

1. In line with it's vision and mission, what should be included in AVMI's value proposition to key stakeholders? (Answers the question why they should support AVMI?)

2. Organization and Structure: How best should the AVMI secretariat be structured and resourced? Numbers? Competencies

3. Prioritize the proposed value propositions listed in (1) above. (Table hosts to capture any other off topic ideas)

Table 3

Goal: **Identify potential Advocacy Champions and Approaches to secure their commitment**

Once the messages AVMI wants to convey to its target audience have been articulated, AVMI will need to identify the right messengers to deliver the messages. Engaging influential individuals to promote change is an innovative and evidence-based advocacy strategy for advancing social, economic, political, and public health issues.

1. Who are the potential advocacy champions which AVMI should reach out to and why? (within countries, RECs, continentally)

2. How should AVMI approach them?   Linkages and introductions?

3. How would you prioritize the above?

(Table hosts to capture any other off topic ideas)

Table 4

Goal: A Framework and Timeframe to convene a Ministerial Conference on Vaccine Development and Manufacture in Africa (MCVDMA)

1. Would you support the idea of a MCVDMA and why?

2. If not, what else?

3. How can AVMI achieve the convening of a MCVDMA?

4. What in your opinion would be a realistic timeframe for achieving it?

(Table hosts to capture any other off topic ideas)